Skip to main content
TipRanks
Go Ultimate75% OFF

Modus Therapeutics Holding AB (MODTX) AI Stock Analysis

0 Followers
SE:MODTX

Modus Therapeutics Holding AB

(Nasdaq OMX AB:MODTX)

Select Model
Rating:41Neutral
Price Target:SEK 0.14â–¼(-4.64% Downside)
Action:reiterated
Date:10/21/26

The score is held down primarily by weak financial performance (pre-revenue, sustained losses and high cash burn implying ongoing funding needs) and very bearish technicals (price far below major moving averages with negative MACD). A debt-free balance sheet and improved equity provide some near-term financial flexibility, but valuation remains difficult to support due to negative earnings and no dividend data.

Positive Factors
Debt-free balance sheetThe absence of debt reduces interest obligations and refinancing exposure while the company advances its development programs. This gives management more flexibility to direct available capital toward clinical work, although it does not eliminate the need for future funding.
Negative Factors
Pre-revenue business modelWith no reported product revenue, Modus currently lacks operating income to fund research and development. Its financial outlook therefore depends on advancing candidates toward future commercialization or transactions, making sustainable business scale unproven over the next several quarters.

Modus Therapeutics Holding AB (MODTX) vs. iShares MSCI Sweden ETF (EWD)

-60%-40%-20%0%20%40%SE:MODTX-59.19%EWD+16.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 25.61M
Dividend Yield
―
Average Volume (3M)
1.24M
Price to Earnings (P/E)
-0.8
Beta (1Y)
2.10
Revenue Growth
―
EPS Growth
0.22%
Country
Sweden
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Modus Therapeutics Holding AB Business Overview & Revenue Model

Company Description

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated w...

How the Company Makes Money

Modus Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it does not appear to generate recurring commercial product revenue. Its business model is primarily to fund and advance its drug development p...

Modus Therapeutics Holding AB Financial Statement Overview

Summary

Overall financial health is weak: the company is pre-revenue with persistent, significant operating and net losses (TTM EBIT about -17.5M; net loss about -17.6M) and materially negative operating/free cash flow (TTM about -18.6M). The main offset is a currently conservative balance sheet with zero debt and improved equity (TTM equity about 10.2M), but returns on equity remain strongly negative and the model depends on continued external funding.

Income Statement

12Very Negative

Balance Sheet

48Neutral

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-17.47M-18.17M-15.84M2,0000-20.69M
Net Income-17.59M-18.54M-15.54M-17.90M-18.32M-20.69M
Balance Sheet
Total Assets13.28M12.69M4.88M20.04M11.27M21.19M
Cash, Cash Equivalents and Short-Term Investments12.49M11.37M4.38M19.06M10.42M20.65M
Total Debt000011.50M0
Total Liabilities3.04M3.62M2.75M2.36M13.86M5.46M
Stockholders Equity10.24M9.07M2.14M17.68M-2.58M15.73M
Cash Flow
Free Cash Flow-18.57M-18.07M-14.68M-16.68M-21.72M-16.08M
Operating Cash Flow-18.57M-18.07M-14.68M-16.68M-21.72M-16.08M
Investing Cash Flow00000-50.00K
Financing Cash Flow29.16M25.07M025.32M11.50M29.43M

Modus Therapeutics Holding AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.15

Price Trends

50DMA0.28Negative
100DMA0.34Negative
200DMA0.36Negative

Market Momentum

MACD-0.03Negative
RSI27.26Positive
STOCH14.58Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MODTX, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.28, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 27.26 is Positive, neither overbought nor oversold. The STOCH value of 14.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MODTX.

Modus Therapeutics Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:MODTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA74OutperformSEK 360.61M1.8863.09%―――
SE:HNSASE:HNSA60NeutralSEK 4.87B-6.06――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BINVSE:BINV49NeutralSEK 172.08M-0.35-128.54%―-83.67%-50.29%
SE:IMMUSE:IMMU48NeutralSEK 228.36M-2.01-19.14%――13.06%
SE:VICOSE:VICO44NeutralSEK 2.90B-5.47-55.97%―-54.97%-1.66%
SE:MODTXSE:MODTX41NeutralSEK 25.61M-0.83-177.45%――0.22%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:MODTXSE:HNSASE:BINVSE:VICOSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:MODTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:MODTXModus Therapeutics Holding AB0.15-0.25-62.53%
SE:HNSAHansa Biopharma47.8820.0672.11%
SE:BINVBioInvent International AB2.62-28.28-91.54%
SE:VICOVicore Pharma Holding AB10.28-0.06-0.58%
SE:IMMUImmunicum AB3.60-2.00-35.71%
SE:CANTACantargia AB1.28-1.95-60.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 21, 2026